Wells Fargo Strategic Capital was among the investors in a series D round valuing the child-focused banking platform developer at $2.3bn.
The CMFG Ventures-backed challenger bank’s latest round valued it at $2.2bn and pushed its total funding past $400m.
The artificial intelligence drug developer has closed a $225m round led by SoftBank Vision Fund 2, which has offered a further $300m in funding.
Koch Disruptive Technologies returned to reinvest in the endpoint cybersecurity software provider, helping boost its overall funding to more than $152m.
Alphabet early-stage investment unit GV has added two biotechnology professionals, Dan Lynch and Mojca Skoberne, to its team.
Renal care provider InterWell Health and skincare product manufacturer Make Essence both raised approximately $46m while Salesforce-backed JazzHR agreed a merger.
Q&A with Gregory Aaron Hoffman, DuPont Electronics & Imaging Ventures
Exor, Coinbase Ventures and DRW Venture Capital have all invested in Crusoe Energy Systems, which owns a network of flared gas-powered data centres.
The Alphabet, Astellas, Novartis and WuXi AppTec-backed T-cell cancer therapy developer has filed to list on the Nasdaq Global Market.
Alphabet and Merck Group could exit the immunological and inflammatory disease therapy developer in an offering with an $86.3m placeholder target.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
